Kondou K, Suzuki T, Chang M, Takaku H
J Biol Eng. 2019; 13:77.
PMID: 31649751
PMC: 6805443.
DOI: 10.1186/s13036-019-0207-y.
Shrestha A, Wijesundara D, Masavuli M, Mekonnen Z, Gowans E, Grubor-Bauk B
Vaccines (Basel). 2019; 7(2).
PMID: 31052178
PMC: 6630607.
DOI: 10.3390/vaccines7020038.
Zanetti B, Ferreira C, de Vasconcelos J, Han S
Gene Ther. 2019; 26(10-11):441-454.
PMID: 30770895
DOI: 10.1038/s41434-019-0062-y.
Elsayed H, Nabi G, McKinstry W, Khoo K, Mak J, Salazar A
J Virol. 2018; 92(14).
PMID: 29743369
PMC: 6026751.
DOI: 10.1128/JVI.00141-18.
Wang C, Dickie J, Sutavani R, Pointer C, Thomas G, Savelyeva N
Front Immunol. 2018; 9:830.
PMID: 29740440
PMC: 5924779.
DOI: 10.3389/fimmu.2018.00830.
A lateral flow assay for the determination of human tetanus antibody in whole blood by using gold nanoparticle labeled tetanus antigen.
Liu J, Wang J, Li Z, Meng H, Zhang L, Wang H
Mikrochim Acta. 2018; 185(2):110.
PMID: 29594594
DOI: 10.1007/s00604-017-2657-6.
Generation of High-Specificity Antibodies against Membrane Proteins Using DNA-Gold Micronanoplexes for Gene Gun Immunization.
Hansen D, Craciunescu F, Fromme P, Johnston S, Sykes K
Curr Protoc Protein Sci. 2018; 91:29.20.1-29.20.22.
PMID: 29516482
PMC: 5846111.
DOI: 10.1002/cpps.50.
Phase I study of an active immunotherapy for asymptomatic phase Lymphoplasmacytic lymphoma with DNA vaccines encoding antigen-chemokine fusion: study protocol.
Thomas S, Cha S, Smith D, Kim K, Parshottam S, Rao S
BMC Cancer. 2018; 18(1):187.
PMID: 29439670
PMC: 5812202.
DOI: 10.1186/s12885-018-4094-2.
The Five Immune Forces Impacting DNA-Based Cancer Immunotherapeutic Strategy.
Amara S, Tiriveedhi V
Int J Mol Sci. 2017; 18(3).
PMID: 28304339
PMC: 5372662.
DOI: 10.3390/ijms18030650.
A plant-expressed conjugate vaccine breaks CD4(+) tolerance and induces potent immunity against metastatic Her2(+) breast cancer.
Chotprakaikiat W, Allen A, Bui-Minh D, Harden E, Jobsri J, Cavallo F
Oncoimmunology. 2016; 5(6):e1166323.
PMID: 27471642
PMC: 4938312.
DOI: 10.1080/2162402X.2016.1166323.
Polyclonal Antibody Production for Membrane Proteins via Genetic Immunization.
Hansen D, Robida M, Craciunescu F, Loskutov A, Dorner K, Rodenberry J
Sci Rep. 2016; 6:21925.
PMID: 26908053
PMC: 4764931.
DOI: 10.1038/srep21925.
Lymphoma Immunotherapy: Current Status.
Zappasodi R, De Braud F, Di Nicola M
Front Immunol. 2015; 6:448.
PMID: 26388871
PMC: 4555084.
DOI: 10.3389/fimmu.2015.00448.
Idiotypic DNA vaccination for the treatment of multiple myeloma: safety and immunogenicity in a phase I clinical study.
McCann K, Godeseth R, Chudley L, Mander A, Di Genova G, Lloyd-Evans P
Cancer Immunol Immunother. 2015; 64(8):1021-32.
PMID: 25982371
PMC: 4506484.
DOI: 10.1007/s00262-015-1703-7.
Plant virus particles carrying tumour antigen activate TLR7 and Induce high levels of protective antibody.
Jobsri J, Allen A, Rajagopal D, Shipton M, Kanyuka K, Lomonossoff G
PLoS One. 2015; 10(2):e0118096.
PMID: 25692288
PMC: 4332868.
DOI: 10.1371/journal.pone.0118096.
Fusion protein vaccines targeting two tumor antigens generate synergistic anti-tumor effects.
Cheng W, Chang M, Sun W, Jen Y, Liao C, Chen Y
PLoS One. 2013; 8(9):e71216.
PMID: 24058440
PMC: 3772923.
DOI: 10.1371/journal.pone.0071216.
An analogue peptide from the Cancer/Testis antigen PASD1 induces CD8+ T cell responses against naturally processed peptide.
Hardwick N, Buchan S, Ingram W, Khan G, Vittes G, Rice J
Cancer Immun. 2013; 13:16.
PMID: 23882161
PMC: 3718735.
Therapeutic cancer vaccines: past, present, and future.
Guo C, Manjili M, Subjeck J, Sarkar D, Fisher P, Wang X
Adv Cancer Res. 2013; 119:421-75.
PMID: 23870514
PMC: 3721379.
DOI: 10.1016/B978-0-12-407190-2.00007-1.
Trial watch: DNA vaccines for cancer therapy.
Senovilla L, Vacchelli E, Garcia P, Eggermont A, Fridman W, Galon J
Oncoimmunology. 2013; 2(4):e23803.
PMID: 23734328
PMC: 3654598.
DOI: 10.4161/onci.23803.
DNA immunization as an efficient strategy for vaccination.
Bolhassani A, Yazdi S
Avicenna J Med Biotechnol. 2013; 1(2):71-88.
PMID: 23407787
PMC: 3558129.
Idiotypes as immunogens: facing the challenge of inducing strong therapeutic immune responses against the variable region of immunoglobulins.
Lopez-Requena A, Burrone O, Cesco-Gaspere M
Front Oncol. 2012; 2:159.
PMID: 23162790
PMC: 3493989.
DOI: 10.3389/fonc.2012.00159.